de Silva, A.P.; Vermeire, S.; Ahmad, T.; Van Heel, D.
(Sri Lanka Medical Association, 2005)
BACKGROUND: Infliximab is effective in two thirds of patients with Crohn's disease (CD) who do not respond to standard therapy. Inherited variants in genes regulating tumour necrosis factor (TNF) expression, metabolism or ...